

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
SPECIAL HEALTH AUTHORITY
CENTRE FOR HEALTH TECHNOLOGY EVALUATION
PROGRESS REPORT

The Board is asked to note this progress report.

Dr Carole Longson

Director
Centre for Health Technology Evaluation

May 2007

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
SPECIAL HEALTH AUTHORITY
CENTRE FOR HEALTH TECHNOLOGY EVALUATION (CHTE)
PROGRESS REPORT

1 Highlights

- The technology appraisal team are looking forward to their team away day on 17 May 2007.
- The final draft of the Interventional Procedures Methods Guide is being considered this meeting of the Board.

2 Progress against business plan objectives (2007 – 2008)

2.1 Technology Appraisals Guidance

Target for year: Publish 17 multiple technology appraisals final appraisal determinations, and 16 single technology appraisals final appraisal determinations.

Target for Q1: Publish 3 multiple technology appraisals final appraisal determinations, and 7 single technology appraisals final appraisal determinations.

Progress: 2 multiple technology appraisals final appraisal determinations have been published either ahead of or to target. 4 single technology appraisals final appraisal determinations have been published either ahead of target or to target and the remaining 3 are expected to publish within the quarter. Please refer to Appendix 1a for further details.

2.2 Interventional Procedure Determinations

Target: Issue 60 Final Interventional Procedure Determinations at a rate of 12 – 18 per quarter.

Progress: 14 Final Interventional Procedure Determinations were scheduled for delivery in Q1. One FIPD was prepared in April and a further nine are scheduled for delivery during the remainder of Q1.

The reduced number is due to two procedures scheduled for consideration by the Interventional Procedures Advisory Committee in November (which would have

been published in April) being withdrawn from the meeting: one because specialist advice could not be obtained in the time available and the other due to changes in the availability of a device which impacted on the scope of the procedure. The affected procedures were:

- *insertion of extraurethral (non circumferential) retropubic adjustable compression devices for stress urinary incontinence in men* - now due to be published in July
- a review of *endoscopic injection of bulking agents for gastro-oesophageal reflux disease* - this was re-scoped as *endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for the treatment of gastro-oesophageal reflux disease*. This is due for publication in July.

A further three procedures considered by the Committee in December, initially due for publication in May, have had publication timelines extended:

- *Arthroscopic knee washout with or without debridement for the treatment of osteoarthritis* – this went for a second consultation as the Committee reformulated the preliminary recommendation following consultation. This is now due for publication in August.
- *Corneal implants for the correction of refractive error* - the Committee decided to consider the two indications of refractive error and keratoconus separately. A further overview needed to be prepared and the two procedures are now scheduled for publication in July.
- Consideration of *image-guided focused ultrasound for uterine fibroids* is delayed pending publication of a major study to be considered by the Committee in preparing its recommendations.

Please refer to Appendix 2 for further details.

2.3 Optimal Practice

Target: Optimal practice – as the NHS continues to seek best value for the funds it has available the Institute will develop its programme of work to produce guidance to support the NHS in disinvesting from ineffective practice.

Progress: In March 2007 a number of workshops, attended by consultees, were held. Papers on the outcome of each workshop are in development and will be presented to the Optimal Practice Steering Group by the end of May 2007.

2.4 Guide to the Methods of Technology Appraisal

Target: Review the Guide to the Methods of Technology Appraisal.

Progress: All workshop & Working Party dates have now been finalised. The public has been informed of the update to the guide and how they can be involved via a press release and details have been posted on the NICE website. The first workshop, on evidence synthesis, is being held 18 May and the final

Working Party Meeting is on 5 September. The next priority is finalising participants for all the workshops and membership of the working party.

2.5 Review Proposal Projects

Target for year: Prepare documentation and consult on review proposals for 19 existing pieces of guidance.

Target for Q1: Prepare documentation and consult on review proposals for 5 existing pieces of guidance.

Progress: Since the beginning of the reporting period 1 review proposal has been sent to consultees and commentators for comment and we are on target for 5 within the quarter. Please refer to Appendix 1b for further details.

2.6 Scoping

Target: Conduct consultation on draft remits and draft scopes, including running scoping workshops for consultees and commentators, for all minded referrals. It is expected that approximately 35 topics will go through this 'block scoping' process within the business planning period (2007-8).

Progress: We await the provisional referral of the 15th wave with 9 topics expected for consultation. We have prepared draft scopes for these topics and organised the scoping workshops in anticipation of the provisional referral, with the first scoping workshop planned for end of June 2007.

2.7 Planning system

Target: Improve the efficiency of the planning and tracking of technology appraisals through the development and implementation of a new planning system.

Progress: Development of the planning system continues. Recruitment of a Data Analyst to lead the final development and implementation of the system is now complete. The successful candidate, subject to references, is expected to join the Institute in Manchester starting early July.

3 Balanced Scorecard

3.1 Critical Success Factor: Publish 33 final appraisal determinations (FAD) for technology appraisals

Key Measures: Publishing of FAD within Stated Quarter

Target: 75%

Progress: In Q1 we anticipate publishing 90% of the planned final appraisal determinations.

3.2 Critical Success Factor: Speed of production

Key Measures: % of single technology appraisals from manufacturer's submission to FAD in 34 weeks

Target: 80%

Progress: Of the 4 single technology appraisals that published final appraisal determinations so far in Q1 2007 – 2008, 50% took 34 weeks or less from receipt of the manufacturer's submission to publication of the final appraisal determination. The appraisals exceeding 34 weeks are shown below:

- Lung cancer – erlotinib took 39 weeks because it was scheduled to allow it to be considered by the committee alongside another lung cancer appraisal.
- Head and neck cancer – cetuximab took 37 weeks because an extra Committee meeting was needed to incorporate evidence from the EMEA into the decision making.

3.3 Critical Success Factor: Speed of production

Key Measures: % of multiple technology appraisals from manufacturer's submission to FAD in 52 weeks

Target: 80%

Progress: Of the 2 multiple technology appraisals that have published final appraisal determinations so far in Q1 2007 – 2008, one took 52 weeks or less from receipt of the manufacturer's submission to publication of the final appraisal determination (heart failure – biventricular pacing). The appraisal exceeding 52 weeks is shown below:

- Glioma (newly diagnosed) – carmustine implants and temozolomide took longer than 52 weeks because this was the second final appraisal determination published for this appraisal. The first final appraisal determination was published in April 2006 but was sent back to Committee for further consideration of extra work undertaken as a result of a miscalculation identified in the Assessment Groups economic modelling.

4 Other Matters

4.1 Interventional Procedures Programme Methods Guide

The IP Programme Methods Guide has been out for public consultation and awaits final approval for publication by the Board. A separate paper has been prepared for consideration by the Board at this meeting, detailing changes proposed as a result of the consultation.

5 Centre Recruitment and Staff

5.1 Technology Appraisals

Laura Bridgman, Administrator has been promoted to Coordinator and joins the Centre for Clinical Practice this month.

Michelle Adhemar, Administrator has been promoted to Coordinator within the Centre and takes up her post this month.

Sarah Garner, Technical Adviser has been promoted to Associate Director, Research and Development, to replace Kalipso Chalkidou during her secondment, and joins the Clinical and Public Health Directorate in July.

Interventional Procedures

Belinda Venter has joined the IP Programme to provide temporary project co-ordination support to the Patient Safety Pilot Project. Belinda will also be providing administrative support to the IP Programme.

Dr Carole Longson
Director, Centre for Health Technology Evaluation

May 2007

Appendix 1a: Publication schedule for final appraisal determinations 2007 - 2008

	Guidance	Process	Technologies	Number covered	Progress
Q1	April – June 2007				
	Lung cancer (non small cell)	STA	erlotinib	1	Final appraisal determination published ahead of target in Q4 2006 – 2007.
	Lung cancer (non small cell)	STA	pemetrexed	1	Final appraisal determination published ahead of target in Q4 2006 – 2007.
	Heart failure	MTA	biventricular pacing (cardiac resynchronization)	5	Final appraisal determination published ahead of target in Q4 2006 – 2007.
	Glioma (newly diagnosed)	MTA	carmustine implants and temozolomide	2	Final appraisal determination published to target in Q1 2007 – 2008.
	Ankylosing spondylitis	MTA	adalimumab, etanercept & infliximab	3	The Committee requested additional work by the Decision Support Unit. The final appraisal determination is not expected to publish on target in Q1. Publication is now expected in Q2.
	Head and neck cancer (locally advanced recurrent metastatic)	STA	cetuximab	1	Final appraisal determination published to target in Q1 2007 – 2008.
	Stroke	STA	alteplase	1	Final appraisal determination published to target in Q1 2007 – 2008.
	Multiple sclerosis	STA	natalizumab	1	Final appraisal determination anticipated to publish to target in Q1 2007 – 2008.
	Psoriatic arthritis	STA	adalimumab	1	Final appraisal determination anticipated to publish to target in Q1 2007 – 2008.
	Multiple myeloma	STA	bortezomib	1	Final appraisal determination anticipated to publish to target in Q1 2007 – 2008.

Q2	July – September 2007				
	Smoking cessation	STA	varenicline	1	
	Rheumatoid arthritis	MTA		3	
	Osteoporosis (primary prevention)	MTA	alendronate, etidronate, risedronate, raloxifene and strontium ranelate	5	
	Osteoporosis (secondary prevention)	MTA	alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide	6	
	Hyper-cholesterolemia	MTA	ezetimibe	1	
	Rheumatoid arthritis	STA	rituximab	1	
	Asthma (uncontrolled)	STA	omalizumab	1	
	Haemorrhoid	MTA	stapled haemorrhoidectomy	2	
	Age-related macular degeneration	MTA	pegaptanib and ranibizumab	2	
	Mesothelioma	MTA	pemetrexed disodium	1	
Q3	October – December 2007				
	Breast cancer (advanced/metastatic)	STA	lapatinib	1	
	Psoriasis	STA	infliximab	1	
	Rheumatoid arthritis	STA	abatacept	1	
	Anaemia (cancer-treatment induced)	MTA	epoetin (alfa & beta) & darbepoetin alfa	3	
	Thrombophilia	MTA	Blood testing kits	20-30	
	Asthma (in adults)	MTA	corticosteroids	tbc	
	Asthma (in children)	MTA	corticosteroids	tbc	
	Glioma (recurrent)	STA	carmustine implants	1	
	Follicular lymphoma (3 rd and subsequent line)	STA (review)	rituximab	1	
Q4	January – March 2008				
	Ischaemic heart disease	MTA	coronary artery stents	12+	
	Sleep apnoea hypopnea syndrome (obstructive)	MTA	continuous positive airway pressure	tbc	
	Ulcerative colitis	STA	infliximab	1	
	Psychosis (first onset)	MTA	Neuroimaging	tbc	

Appendix 1b: Publication schedule for Review Proposals 2007-2008

	Guidance	Progress
Q1	April – June 2007	
	Guidance no. 77 Insomnia - newer hypnotic drugs	Consultation anticipated starting on target in Q1 2007 – 2008.
	Guidance no. 78 Menstrual bleeding - fluid-filled thermal balloon and microwave endometrial ablation	Consultation anticipated starting on target in Q1 2007 – 2008.
	Guidance no. 107 Breast cancer (early) – trastuzumab	Consultation anticipated starting on target in Q1 2007 – 2008.
	Guidance no. 108 Breast cancer (early) – paclitaxel	Consultation anticipated starting on target in Q1 2007 – 2008.
	Guidance no. 109 Breast cancer (early) – docetaxel	Consultation anticipated starting on target in Q1 2007 – 2008.
Q2	July – September 2007	
	Guidance no. 47 Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors	
	Guidance no. 80 Acute coronary syndromes – clopidogrel	
	Guidance no. 81 Atopic dermatitis (eczema) - topical steroids	
	Guidance no. 95 Arrhythmia - implantable cardioverter defibrillators (ICDs)	
	Guidance no. 104 Psoriatic arthritis - etanercept and infliximab	
	Guidance no. 82 Atopic dermatitis (eczema) – pimecrolimus and tacrolimus	
	Guidance no. 83 Hernia – laparoscopic surgery	
	Guidance no. 85 Renal transplantation - immuno-suppressive regimens (adults)	
	Guidance no. 84 Sepsis (severe) – drotrecogin	
	Guidance no. 102 Conduct disorder in children - parent-training/education programmes	
Q3	October – December 2007	
	Guidance no. 106 Hepatitis C - peginterferon alfa and ribavirin	
	Guidance no. 23 Glioma (recurrent) – temozolomide	
Q4	January – March 2008	
	Guidance no. 94 Cardiovascular disease – statins	

	Guidance no. 91 Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)	
--	--	--

Appendix 2: Schedule of Interventional Procedures planned guidance for 2007/8 publication

Dates in **bold** are past or fixed. Dates in *italics* are targets.

Procedure name	Topic area	Quarter of publication (scheduled)	Quarter of publication (actual/due)
Tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium	Eye	Q1 2007/08	Q1 2007/08
Ultrasound-guided foam sclerotherapy for varicose veins	Cardiovascular	Q1 2007/08	Q1 2007/08
Therapeutic sialendoscopy	Mouth and dental	Q1 2007/08	Q1 2007/08
Microwave ablation for the treatment of metastases in the liver	Digestive system	Q1 2007/08	Q1 2007/08
Lower limb deep vein valve reconstruction for chronic deep venous incompetence	Cardiovascular	Q1 2007/08	Q1 2007/08
Transcranial magnetic stimulation for severe depression	Mental health and behavioural conditions	Q1 2007/08	Q1 2007/08
Closure of anorectal fistula using a suturable bioprosthetic plug	Digestive system	Q1 2007/08	Q1 2007/08
Percutaneous image guided aspiration of spinal cord cysts	Central nervous system	Q1 2007/08	Q1 2007/08
Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for the treatment of gastro-oesophageal reflux disease	Digestive system	Q1 2007/08	Q1 2007/08
Corneal implants for the correction of refractive error	Eye	Q1 2007/08	Q2 2007/08
Arthroscopic knee washout with or without debridement for the treatment of osteoarthritis	Musculoskeletal	Q1 2007/08	Q2 2007/08
Insertion of extraurethral (non-circumferential) retropubic adjustable compression devices for stress urinary incontinence in men	Urogenital	Q1 2007/08	Q2 2007/08
Magnetic resonance (MR) image-guided transcuteaneous focused ultrasound ablation for uterine fibroids	Gynaecology, pregnancy and birth	Q1 2007/08	Pending publication of study
Laparoscopic deroofting of simple renal cysts	Central nervous system	Q2 2007/08	Q2 2007/08
Corneal implants for keratoconus	Eye	Q2 2007/08	Q2 2007/08
Laparoscopic cervical cerclage for prevention of recurrent pregnancy loss due to cervical incompetence	Gynaecology, pregnancy and birth	Q2 2007/08	Q2 2007/08

Procedure name	Topic area	Quarter of publication (scheduled)	Quarter of publication (actual/due)
Laparoscopic repair of abdominal aortic aneurysm	Cardiovascular	Q2 2007/08	Q2 2007/08
Laparoscopic uterine nerve ablation (LUNA) for chronic pelvic pain	Gynaecology, pregnancy and birth	Q2 2007/08	Q2 2007/08
Endovascular stent insertion for intracranial atherosclerotic disease	Cardiovascular	Q2 2007/08	Q2 2007/08
Serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition dependent children	Digestive system	Q2 2007/08	Q2 2007/08
Intravesical microwave hyperthermia with intravesical chemotherapy for superficial bladder cancer	Urogenital	Q2 2007/08	Q2 2007/08
Grenz rays therapy for inflammatory skin conditions	Skin	Q3 2007/08	Q3 2007/08
Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction	Cardiovascular	Q3 2007/08	Q3 2007/08
Mini/micro screw implantation for orthodontic anchorage	Mouth and dental	Q3 2007/08	Q3 2007/08
Laparoscopic techniques for hysterectomy	Gynaecology, pregnancy and birth	Q3 2007/08	Q3 2007/08
Thoracoscopic aortopexy for severe tracheomalacia	Musculoskeletal	Q3 2007/08	Q3 2007/08
Soft palate implants for snoring	Mouth and dental	Q3 2007/08	Q3 2007/08
Soft palate implants for obstructive sleep apnoea	Mouth and dental	Q3 2007/08	Q3 2007/08
RF Ablation for Barrett's Oesophagus	Digestive system	Q3 2007/08	Q3 2007/08
Endoscopic vein harvest for CABG	Cardiovascular	Q3 2007/08	Q3 2007/08
Minimally invasive mitral valve surgery	Cardiovascular	Q3 2007/08	Q3 2007/08
Occipital nerve stimulation for migraine	Central nervous system	Q3 2007/08	Q3 2007/08
Ultrasound visualisation of the epidural space	Miscellaneous	Q3 2007/08	Q3 2007/08
Thorascopic excision of ectopic mediastinal (subpleural) parathyroid adenoma	Ear and nose	Q3 2007/08	Q3 2007/08
Excimer laser assisted, nonocclusive, cerebral vascular anastomosis (ELANA)	Central nervous system	Q3 2007/08	Q3 2007/08
Uterine nerve ablation (UNA)	Gynaecology, pregnancy and birth	Q3 2007/08	Q3 2007/08
Minimally invasive aortic valve surgery	Cardiovascular	Q3 2007/08	Q3 2007/08
Liposuction for lymphoedema	Miscellaneous	Q4 2007/08	Q4 2007/08